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Summary
Background: Acute bacterial meningitis remains an important cause of morbidity, neurologic
sequelae, and mortality in children in Latin America.
Methods: We retrospectively reviewed the hospital-based medical records of children diagnosed
with acute bacterial meningitis, aged 1 month to 18 years, at a large inner city referral Hospital in
Mexico City, for a 10-year period (1993—2003). To characterize the epidemiology, clinical
features, and outcomes of acute bacterial meningitis, we subdivided our study into two time
periods: the period prior to the routine use of Haemophilus influenzae type b (Hib) vaccine
(1993—1998) and the period after the vaccine became available (1999—2003).
Results: A total of 218 cases of acute bacterial meningitis were identified during the study
period. The most frequently affected age group was that of children aged between 1 and 6
months. Hib was the most commonly isolated pathogen, found in 50% of cases. However, its
incidence declined significantly after the introduction of the combined diphtheria, tetanus,
pertussis, hepatitis B, and conjugated Hib (DTP—HB/Hib) pentavalent vaccine into the universal
vaccination schedule for children in 1998. Streptococcus pneumoniae followed as the second
most commonly isolated bacterial pathogen. Neisseria meningitidis was isolated in only a few
cases, confirming the historically low incidence of this pathogen in Mexico. Identified risk factors
for death were found to include the presence of septic shock and intracranial hypertension, but
were not attributable to any particular bacterial pathogen.
Conclusions: In our hospital, acute bacterial meningitis remains a severe disease with important
sequelae andmortality. The incidence of Hibmeningitis cases has declined since the introduction of
the Hib vaccine. However, S. pneumoniae persists as an important cause of bacterial meningitis,
highlighting the need for the implementation of vaccination policies against this pathogen.
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Acute bacterial meningitis (BM) constitutes a significant
global public health problem. Worldwide, it has been esti-
mated that 1—2 million cases of BM occur annually.1—4 The
problem is more significant in resource-poor countries includ-
ing those in some regions of Sub-Saharan Africa, Southeast
Asia, and Latin America.5,6
The initial treatment approach to a child with suspected
BM depends on early recognition of the meningitis syndrome,
rapid diagnostic evaluation, and early antimicrobial and
adjunctive therapy.7—9 Once suspected, blood cultures, cra-
nial computed tomography (CT scan) when indicated, and
lumbar puncture to obtain cerebrospinal fluid (CSF) for
examination is considered the standard of care. Management
algorithms for BM in children include the initiation of dex-
amethasone plus empirical antimicrobial therapy.10—12 How-
ever, BM remains a neurological and infectious disease
emergency with a high mortality rate, despite advances in
diagnostic techniques, antimicrobial chemotherapy, and
adjuvant use of anti-inflammatory agents.10 Sequelae, such
as hearing loss, blindness, seizure disorders, hydrocephalus,
developmental delay, and motor deficit occur even with the
rapid institution of adequate therapy.11,12 Indeed, BM can
often be rapidly progressive, resulting in permanent sequelae
in a relatively short period of time.11 This is the reason why
vaccination strategies to prevent the invasive bacterial dis-
ease of organisms capable of causing meningitis, such as
Haemophilus influenzae type b (Hib) and Streptococcus
pneumoniae, are considered public health priorities.13—
19While there are six serotypes of Haemophilus influenzae
known to cause disease, type b is responsible for over 90% of
BM in children.5,16,18 Indeed, prior to the widespread use of
conjugate vaccines against Hib, this organism was the most
common cause of severe invasive infections in children,
resulting in approximately 300 000 to 500 000 deaths
annually worldwide. In the USA, with the advent of the
Hib conjugate vaccine, Hib cases in children under 5 years
of age declined by 99% from 1986 to 1995; this decline has
also occurred in other resource-rich countries. This beneficial
shift in the epidemiology of BM prompted the World Health
Organization (WHO) to recommend that the Hib vaccine
should be included in routine infant immunization programs
for all children, as appropriate to national capacities and
priorities.5,15With these dynamic changes in the epidemiol-
ogy of BM in many areas of the world resulting in decreasing
numbers of cases due to Hib, S. pneumoniae and Neisseria
meningitidis have become the predominant causes of menin-
gitis in children aged 1 month and older.13 In fact, recent
WHO estimates have suggested that approximately 1.6 mil-
lion people die of pneumococcal disease every year, including
0.7—1 million children under 5 years of age, most of whom
are from resource-poor countries.11,13 This is the rationale
behind the WHO and other leading public health agencies
promoting the introduction of a conjugate pneumococcal
vaccine into routine childhood immunization programs. In
addition, countries are encouraged to conduct appropriate
surveillance for pneumococcal disease to establish the base-
line and monitor the impact of vaccination.13
In Mexico, BM remains an important cause of morbidity,
neurologic sequelae, and mortality. However, there are lim-
ited epidemiologic and microbiologic data on this disease inchildren and adults.7 In particular, there are limited data
evaluating the impact of routine childhood vaccination
against Hib, which was initiated in 1998. Therefore, we
conducted this comprehensive, hospital-based retrospective
study to describe the epidemiology, clinical features, and
outcomes for Mexican children with BM aged 1 month and
older, seen at the Hospital Infantil de Me´xico Federico
Go´mez, a major national pediatric referral center.
Methods
We retrospectively reviewed the hospital-based medical
records of children diagnosed with acute BM, aged 1 month
to 18 years (beyond the neonatal period), evaluated at the
Hospital Infantil de Me´xico Federico Go´mez (HIMFG), for a 10-
year period (1993—2003). Founded in 1943, HIMFG is the
oldest of Mexico’s 12 National Institutes of Health, and is
the leading national referral pediatric institution. The study
period was subdivided into the period prior to the introduc-
tion of the conjugate Hib vaccine (1993—1998) and the period
after its introduction (1999—2003).
We included 218 cases of BM based on the presence of
clinical symptoms consistent with a meningitis syndrome and
the following ancillary laboratory criteria: (1) positive bac-
terial culture in CSF; (2) CSF pleocytosis 5  106/l with a
negative CSF culture plus one of the following: positive
blood culture, positive CSF antigen test, positive Gram stain
of the CSF, or a positive throat culture for N. meningitidis in
patients with a purpuric rash; (3) CSF pleocytosis 5  106/l
with a negative CSF culture, negative blood or throat culture,
or negative co-agglutination test. We excluded patients with
tuberculous meningitis, immunocompromised patients, and
cases of nosocomial meningitis. Demographic data (including
age and gender) and data on symptoms at presentation,
physical examination on admission, previous vaccination
schedule, laboratory results, CSF examination, CT scan
results, and treatment and outcomes were collected using
a standarized data collection form. Death due to BM was
classified as meningitis-related if death was secondary to
meningitis or any of its complications as recorded by the
medical record and/or autopsy data.
Statistical analysis was carried out by proportion compar-
isons using the Mantel—Haenszel Chi-square test or Fisher’s
exact test as appropriate. The Wilcoxon rank sum test was
used to compare medians of continuous variables when the
two-sample t-test was not appropriate. All tests were two-
sided and a p-value of 0.05 was considered significant. To
determine the association between potential risk factors and
death due to BM, logistic regression was used to estimate
odds ratios (OR) and their 95% confidence intervals (CI).
Those variables that in bivariate analysis would have
achieved a significance level of 0.05 were included in the
model as main effects, along with effect modifiers and
confounders of the association between death and shock
(our main outcome of interest). A hierarchical backwards
elimination strategy was performed, with proper evaluation
of interaction and confounding. The goodness of fit of the
model was assessed using the Hosmer and Lemeshow Chi-
square test. Assessment of collinearity was done by analyzing
the condition indices and the respective variance decompo-
sition proportions (VDPs). All statistical analyses were per-
formed using SAS software (version 8.2, SAS Institute, Cary,
382 C. Franco-Paredes et al.NC, USA). The study was approved by the research committee
of the Hospital Infantil de Me´xico Federico Go´mez.
Results
A total of 218 cases met the inclusion criteria for our study. Of
these, 131 were male and 87 were female. When we divided
the number of cases by age group, we identified 85 cases in
infants between 1 and 6 months of age, 56 cases in those
between 6 months and 12 months of age, 61 cases in children
aged between 1 and 5 years, and 16 cases in children older
than 5 years.
During the initial study period (1993—1998), there were
159 (73%) children with BM, while there were 59 (27%) cases
during the second period (1999—2003) (Table 1). Overall, Hib
was the most common pathogen (by CSF culture and/or co-
agglutination testing in CSF), causing 50% (109/218) of the
cases; S. pneumoniae was isolated in 31% (67/218) of cases
and N. meningitidis in only 2% (4/218) during the two study
periods. Other pathogens, particularly Gram-negative bac-
teria, were found in 6% (14/218) of cases. In 11% (24/218) of
cases, no pathogen was identified but the patient met the
clinical criteria for BM according to our study inclusion
criteria.
With regards to the etiological cause of BM according to
age group, we found that pneumococcal disease occurred in
all age groups, but was more frequent in children 1 year of
age. Cases of BM due to Hib occurred equally in all age
groups; however we noted a trend for it to occur more
frequently in children aged between 6 months and 3 years
in the pre-vaccination period. In the period following the
availability of the Hib vaccine, we noted that 6/8 (75%) Hib
cases arose in children aged 4 years and over who had not
previously been vaccinated. However, 2/8 (25%) cases
occurred in children who had received at least two doses
of Hib vaccine at the time BM was diagnosed (in the group of
children aged between 6 and 12 months).
When we analyzed microbiological causes by study period
(1993—1998 vs. 1999—2003), we identified that prior to the
introduction of the Hib vaccine (1993—1998 period) the most
frequent pathogen was Hib in 64% of cases; S. pneumoniae
occurred in 22%, and N. meningitidis in 0.5% of cases. Other
pathogens were found in 5.5% of cases and no bacterial
pathogen was found in 8%.Table 1 Number of cases of acute bacterial meningitis accordin
pathogen, among 218 pediatric patients with acute bacterial menin
Bacterial pathogen Total No.
cases (%) a
Perio
intro
1993
All pathogens 218 (100%) 159
Haemophilus influenzae type b 109 (50%) 101
Streptococcus pneumoniae 67 (31%) 35
Neisseria meningitidis 4 (2%) 1
Other pathogen 14 (6%) 9
No pathogenc 24 (11%) 13
a Absolute numbers are shown in this table. Rates not shown.
b Six out of eight (75%) of the cases were in children aged 4 years an
c Clinical cases of acute bacterial meningitis (by signs, symptoms, an
blood cultures).The number of Hib meningitis cases during the 1999—2003
study period was eight (14%); S. pneumoniae was found in
54%, N. meningitidis in 5%, other pathogens in 8%, and no
pathogen in 19% of cases (Table 1). Therefore, the incidence
of Hib decreased from 64% to 14% ( p < 0.001) following the
introduction of the Hib vaccine, in absolute numbers and also
by rates when adjusted to the number of admissions per year
(data not shown). Cases of S. pneumoniae were not signifi-
cantly different between the two periods.
With regards to the clinical manifestations of BM, 45 of the
218 (21%) patients presented at admission with the classic
clinical triad of fever, altered mental status, and nuchal
rigidity. The most common clinical features were fever in
92%, vomiting in 55%, irritability in 54%, and focal neurologic
findings in 36% of patients. Fever was highly prevalent in all
age groups. Focal neurologic findings were more commonly
seen in children over 5 years of age ( p = 0.0006). A history of
seizure disorder occurring during hospitalization was present
in 54% of our patients, and it was most commonly seen in
children aged 6 to 12 months ( p = 0.0169). In addition, the
findings of neck stiffness and meningismus increased with
increasing age, and these two signs were more frequent in
children older than 5 years of age ( p = 0.0002 and
p < 0.0001, respectively). A bulging fontanelle was identified
in 27% of children aged less than 6 months ( p < 0.0001)
(Table 2).
With respect to laboratory values, almost two thirds of
patients with BM developed anemia during the course of their
hospitalization. In addition, leukocytosis was present in 70%
of patients. However, only 9% developed thrombocytopenia
and most of these cases occurred during the course of septic
shock episodes. Hyponatremia was found in 13% of patients
during the course of their hospitalization. Blood cultures
were positive in 6% of a total of 203 patients from whom
blood cultures were obtained. Interestingly, of the 106 cases
of Hib-related meningitis, 83% had anemia compared to only
between 11% and 20% for other bacterial pathogens
( p = 0.003).
Lumbar puncture was performed in 201 of the 218 BM
cases; this procedure was contraindicated in the remaining
cases due to a high risk of brain herniation. Cerebrospinal
fluid pleocytosis was a common finding, identified in 96%
of our patients. The CSF protein level was elevated in 95% of
cases, and the glucose level was considered low in 78% ofg to study period (1993—1998 and 1999—2003) and bacterial
gitis (Hospital Infantil de Me´xico Federico Go´mez, 1993—2003)
d before the
duction of Hib vaccine,
—1998 No. cases (%)
Period after the
introduction of Hib vaccine,
1999—2003 No. cases (%)
(100%) 59 (100%)
(64%) 8 (14%)b
(22%) 32 (54%)
(0.5%) 3 (5%)
(5.5%) 5 (8%)
(8%) 11 (19%)
d over who had not received previous Hib vaccination.
d CSF pleocytosis, but negative co-agglutination, CSF cultures, or
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Table 2 Prevalence of clinical manifestations by age group among 218 pediatric patients with acute bacterial meningitis (Hospital
Infantil de Me´xico Federico Go´mez, 1993—2003)
Clinical manifestations (N = 218) 1—6 months 6—12 months 1—5 years >5 years Chi-square p-Value Fisher’s
exact test
Fever 89.4 92.8 98.3 81.25 NA 0.0498
Seizure disorder 54.1 75.4 40.9 25 5.7 0.0169
Irritability 64.71 46.4 55.7 18.7 7.14 0.0075
Altered mentation 23.5 35.7 49.1 56.2 12.94 0.0003
Focal neurologic signs
(sensory or motor deficits)
28.2 30.3 40.9 81.2 11.93 0.0006
Vomiting 44.7 58.9 65.5 62.5 5.926 0.0149
Meningeal signs 27.0 41.0 50.8 75.0 16.22 <0.0001
Neck stiffness 48.2 51.7 68.8 93.75 13.54 0.0002
Feeding avoidance 43.5 46.4 50.8 31.2 0.0026 0.9595
Prostration 12.9 8.93 32.7 31.2 9.51 0.0020
Headache 2.35 8.93 24.5 75.0 46.09 <0.0001
Bulging fontanelle 27.06 17.8 4.9 0.00 15.65 <0.0001cases. The classic triad of CSF pleocytosis, increased total
protein, and a low glucose level was present in 78% of cases.
Only in 50% of patients was the Gram stain positive. Co-
agglutination was clinically useful in confirming a diagnosis in
56% of cases when CSF culture was reported as negative.
Most patients in our series, 156 of the 218 (71%), under-
went CT cranial imaging at some point during their hospital
stay. Of these, 29% had findings that were consistent with
cerebral edema, 43%manifested subdural effusion, 11% had a
brain abscess, 14% had a cerebral infarct, 11% had hydro-
cephalus, and 13% had findings consistent with brain atrophy.
The presence of headache ( p = 0.0278), seizure disorder
( p = 0.0001), and fever ( p = 0.021) were independent risk
factors for developing a hygroma in cranial CT imaging, while
having a bulging fontanelle was a risk factor for cerebral
edema ( p = 0.0031) (Table 3).
A total of 36 (16%) patients died as a result of BM and its
complications. In a multivariable logistic regression analysis,
septic shock and intracranial hypertension were identified as
independent risk factors for death. However, we did not find
any statistically significant difference between bacterial
pathogens for the risk of death (Table 4). The most common
complication identified in our series was seizure disorder in
37% of patients, followed by subdural empyema in 26%, and
shock in 24% of cases. A full recovery occurred in 82 (38%)
patients. Of the remaining 100 (46%) patients who survived,
the most common neurologic sequelae were persistent
seizure disorder, occurring in 37%, followed by hearing loss
(32%).
Discussion
Acute BM is a significant cause of morbidity and mortality in
children in Latin America across all age groups. However,
neurologic sequelae and mortality seem particularly high in
the pediatric population.18—21 The results of this study con-
firm that the clinical features and outcomes in children with
BM are similar to those reported in previous studies from
Latin America and other countries.22,23 In addition, we found
that anemia was most frequently associated with Hib menin-
gitis, as has been reported in other series.5,8,18 Regardingclinical outcomes, we identified that septic shock and intra-
cranial hypertension were independent risk factors for
death, but were unable to identify an increased risk attri-
butable to any particular bacterial pathogen. Furthermore,
we identified that among survivors there was a high rate of
permanent neurologic sequelae including seizure disorder
and/or hearing loss, confirming that these complications
continue to occur despite the institution of adequate therapy
in children.5,6,11 In fact, the results of our study confirm that
BM continues to be a medical, neurological, and sometimes
neurosurgical emergency that requires a multidisciplinary
approach.10
With regards to the specific complications that could be
attributed to specific bacterial pathogens, it has been esti-
mated that most of the mortality due to Hib in Latin America,
and worldwide, occurs in children aged <5 years.5,8,12,14,16—
18 The long-term complications of Hib-associated BM, such
as hearing loss, have been used as standard indicators
for comparing Hib disease burden between and within
countries.5,16
Many factors can affect the quality of population-based
studies of Hib meningitis, including patient access to and
utilization of medical services, pre-treatment of patients
with antibiotics, and quality of laboratory diagnostic meth-
ods. We found that at our institution, the occurrence of Hib
meningitis has decreased over time, while that of S. pneu-
moniae has remained constant.16 The importance of preven-
tive strategies such as the use of Hib and pneumococcal
conjugate vaccination is highlighted by the fact that despite
the effectiveness of current antibiotic regimens in clearing
bacteria from the CSF, BM continues to cause substantial
morbidity and mortality worldwide.5,16 This may be due to
the underlying pathogenesis of the disease, given the fact
that much of the damage from this infection is believed to
result from cytokines and the ensuing inflammatory infiltra-
tion within the CSF.6,23,24In Latin America, in 1994, Uruguay
became the first country to include the Hib vaccine in their
routine immunization program. Following the lead of Uru-
guay, Chile also introduced Hib vaccination, since many
clinical trials to evaluate the safety, immunogenicity, and
efficacy of the Hib vaccine were conducted in this country.5 It
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Table 3 Prevalence of cranial CT findings in association with clinical manifestations among 218 pediatric patients with acute
bacterial meningitis (Hospital Infantil de Me´xico Federico Go´mez, 1993—2003)
Cerebral edema Hygroma
Clinical manifestations No. Prevalence (%) Chi-square p-Value Fisher’s Prevalence (%) Chi-square p-Value
Fever
Yes 201 19.40 NA 0.1269 32.84 5.32 0.021
No 17 32.29 5.88
Seizures
Yes 117 24.79 2.635 0.1045 41.88 14.67 0.0001
No 101 15.84 17.82
Irritability
Yes 118 22.88 0.784 0.376 34.75 1.93 0.1641
No 100 18.0 26.00
Altered mentation
Yes 79 25.32 1.645 0.1996 26.58 0.999 0.3177
No 139 17.99 33.09
Focal neurologic signs
Yes 79 22.78 0.346 0.5566 29.11 0.152 0.6966
No 139 19.42 31.65
Vomiting
Yes 121 23.97 1.827 0.1765 31.40 0.057 0.8109
No 97 16.49 29.90
Meningeal signs
Yes 82 22.47 0.306 0.5802 25.84 1.683 0.1946
No 129 19.38 34.11
Neck stiffness
Yes 127 21.26 0.071 0.7906 28.35 0.811 0.3679
No 91 19.78 34.07
Feeding avoidance
Yes 99 23.23 0.739 0.3899 32.32 0.214 0.6435
No 119 18.49 29.41
Prostration
Yes 41 21.95 0.053 0.8186 24.39 0.950 0.3297
No 117 20.34 32.20
Headache
Yes 34 17.65 0.220 0.6394 14.71 4.839 0.0278
No 184 21.20 33.70
Bulging fontanelle
Yes 36 38.89 8.724 0.0031 33.33 0.136 0.712
No 182 1703 30.22soon became clear that BM due to Hib had declined signifi-
cantly in these two countries following the introduction of
the Hib vaccine. By 1998, with the support of the Pan-
American Health Organization (PAHO) revolving fund for joint
purchases of vaccine, more than 15 other countries in Latin
America and the Caribbean integrated the Hib vaccine into
their routine immunization programs.5,15,22
Subsequent studies from Chile and Uruguay have demon-
strated the importance of evaluating the epidemiology and
burden of disease associated with BM in the region after the
introduction of Hib vaccination.5,16 In 1999, Mexico was the
first country to introduce Hib vaccination using the penta-
valent combination vaccine in a three-dose schedule withouta booster.25,26 The decision to use this combination vaccine
was reached after documenting that high anti-PRP antibody
concentrations were reached 1month after vaccination, with
100% of seroprotected subjects in the combined vaccination
group (antibody concentrations 0.15 mg/ml) against 99.4%
in the separate injection vaccination group.27 By the end of
that year the DTP—HB/Hib vaccine had been distributed to
87% of Mexican children under 1 year of age.25,26 By the end
of 1999, more than 800 000 doses of pentavalent vaccine had
been administered in Mexico.26 It is noteworthy that in the
study period following the introduction of the Hib combina-
tion vaccine, 6/8 (75%) of BM cases were in children who had
not received previous Hib vaccination because they were
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Table 4 Adjusted odds ratios for death among 218 pediatric
patients with acute bacterial meningitis (Hospital Infantil de
Me´xico Federico Go´mez, 1993—2003)
Risk factors for death OR 95% CI p-Value
Shock
Yes 25.56 9.19—71.10 <0.001
No 1.00
Intracranial hypertension
Yes 6.63 2.25—19.55 0.001
No 1.00
Bacterial pathogen
Haemophilus
influenzae type b
0.35 0.11—1.08 0.068
Streptococcus
pneumoniae
1.08 0.34—3.47 0.896
Other pathogen 1.00
OR, odds ratio; CI, confidence interval.born prior to the initiation of universal vaccination, and the
two vaccinated infants had not yet received the third dose.
Recent serological evidence has shown that the pentavalent
vaccination in a well defined cohort of children between the
ages of 7 and 93 months, demonstrated serum IgG concen-
trations >0.15 mg/ml.28 These serological titers have been
shown to confer protection against Hib invasive disease.28
Therefore, the purpose of our study was to define the
leading pathogens causing community-acquired meningitis
(beyond the neonatal period) in a pediatric population in a
major referral pediatric hospital in Mexico City. The causa-
tive organisms found in a particular region vary with the
patient’s age and general health, and with the immunization
status of the community. The results of our study provide
some evidence that with the implementation of routine Hib
vaccination in children in Mexico since 1998, the number of
cases of BM due to Hib in children has decreased. With the
availability of routine Hib pentavalent vaccination, cases of
BM due to Hib mostly occurred among the cohort of older
unvaccinated children, with only two cases occurring in
previously vaccinated children in their first year of life.
Among different pediatric series, the most important
causative organisms of BM are S. pneumoniae, N. meningi-
tidis, and Hib.5—7,23,24 S. pneumoniae continues as a persis-
tent pathogen causing BM.13,29 Universal vaccination of
children <2 years of age with a conjugate pneumococcal
vaccine has demonstrated three important benefits at a
population level: (1) a substantial decrease in invasive dis-
ease and otitis media among vaccinees; (2) herd immunity
protection in adults by decreasing the rates of invasive
disease by 67% at a population level; and (3) a decrease in
the circulation of antibiotic-resistant pneumococcal sero-
types.13,29 The impact of S. pneumoniae vaccination in chil-
dren may prove to be an effective strategy to prevent the
occurrence of BM. In Mexico, CONAVA, the National Immu-
nization Council, has started to routinely vaccinate some
underserved pediatric groups in some areas of the country.
The impact of this program is currently under scrutiny.
Approximately 500 million people worldwide are carriers
of N. meningitidis in their nasopharynx, but only some
develop meningococcemia or meningitis syndrome.30 Mostof the burden of meningococcal meningitis occurs in Sub-
Saharan Africa. In Latin America, most of the outbreaks of N.
meningitidis have been recorded in the Southern Cone coun-
tries and in Cuba.7,30 In Mexico, the last confirmed epidemic
of N. meningitidis was documented in the central part of the
country in 1945. Since then, the number of registered cases
has persisted at a low level despite substantial increases in
population density in areas of major population concentra-
tion. In our series, we confirmed the registered historically
low incidence of BM due to N. meningitidis in children in our
country. Indeed, these rates of BM due to N. meningitidis in
Mexico have recently been confirmed by the current pro-
spective national epidemiologic surveillance system.7
As our study was retrospective and hospital-based, under-
estimating the actual number of cases is a potential bias. We
attempted to overcome this limitation by collecting data on
every patient seen at our institution using multiple over-
lapping hospital databases in order to reduce the likelihood
of omitting patients. Hospital-based epidemiologic data have
been suggested to provide relevant data on vaccine effec-
tiveness against Hib.18 In addition, while this was a single
center study, it is relevant to point out that our institution is a
regional referral public hospital for a substantial area of
Mexico City and neighboring Mexican states. In Mexico, the
vast majority of children with BM are managed at referral
public hospitals such as ours. In addition, by reviewing only
the community-acquired cases of acute BM, and excluding
neonatal and nosocomial meningitis cases, we attempted to
indirectly evaluate what is really occurring in the larger
community.6 Since our group has previously demonstrated
the impact of routine pediatric BCG vaccination as ameans of
reducing TB meningitis at a population-based level,31 we also
excluded cases of TB meningitis from this analysis.
In summary, our hospital-based retrospective analysis,
albeit with some limitations, demonstrates that BM is a
severe disease that produces significant sequelae and mor-
tality. Since our institution is a referral center for many
regions of the country, we believe that our data may be used
as a surrogate marker of what is occurring in the larger
community. Given the significant morbidity and mortality
associated with BM despite the availability of medical ther-
apy, we believe that most efforts should focus on preventing
cases through routine vaccination programs. We conclude
that our data suggest that the incidence of Hib meningitis has
declined following the introduction of the Hib vaccine in our
pediatric population, and S. pneumoniae meningitis con-
tinues to be a persistent pathogen. These data highlight
the need for the implementation or the broadening of cover-
age for already existing vaccination programs in children
against S. pneumoniae to prevent BM among vaccinees and
to produce indirect herd immunity for other age groups.
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